Home » Pipeline
|Aravive Biologics, Inc.
|Platinum-resistant ovarian cancer
|Granted Fast Track Designation by the FDA
|Social anxiety and public speaking anxiety disorders
|Positive data from a proof-of-concept Phase III clinical trial
|Sun Pharmaceutical Industries Ltd.
|Cequa (cyclosporine ophthalmic solution) 0.09 percent
|Keratoconjunctivitis sicca (dry eye)
|Approval granted by FDA
|Lion TCR Pte. Ltd.
|Relapsed liver cancer post-liver transplantation
|Approval granted by Health Sciences Authority (HSA), Singapore, for multicenter Phase I/II clinical trial
|Taiwan Liposome Company, Ltd.
|TLC590, a proprietary BioSeizer™ liposomal formulation of ropivacaine
|Dosing of first patients in a Phase I/II trial
|Generic version of EpiPen Auto-Injector
|Severe allergic reactions
|Approval granted by the FDA
|Tislelizumab, an investigational anti-PD-1antibody, combined with chemotherapy as a potential first-line treatment
|Stage IIIB or IV squamous non-small cell lung cancer (NSCLC)
|Phase III clinical trial initiated
|Eiger BioPharmaceuticals, Inc.
|Avexitide (formerly exendin 9-39)
|Post-bariatric surgical patients who experience post-bariatric hypoglycemia (PBH)
|Completion of enrollment in Phase II clinical trial
|Escalier Biosciences, BV
|ESR-114 topical gel
|Phase I/IIa clinical trial initiated
|Sangamo Therapeutics, Inc.
|SB-525, a cDNA gene therapy candidate
|Positive preliminary data from the Phase I/II clinical trial
|ADCT-402 (loncastuximab tesirine)
|Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
|Phase II clinical trial initiated
|Alexion Pharmaceuticals, Inc.
|ALXN1210, investigational long-acting C5 complement inhibitor
|Paroxysmal nocturnal hemoglobinuria (PNH)
|FDA accepted Biologics License Application (BLA) for approval
|Merck & Co.
|Keytruda in combination with Alimta (pemetrexed) and platinum chemotherapy as first-line treatment
|Metastatic non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations
|Granted approval by the FDA
|SPRING endura (single lead) and extensa (dual lead) Peripheral Nerve Stimulation (PNS) Systems
|Cleared by the FDA
|Luminelle DTx Hysteroscopy System
|Hysteroscopy and cystoscopy
|Received 510(k) clearance from the FDA
|Tolero Pharmaceuticals, Inc.
|Combination therapy with AbbVie’s venetoclax and Tolero’s investigational agent
|Relapsed/refractory acute myeloid leukemia (AML)
|Tolero Pharmaceuticals and AbbVie partner for trial
Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials
Learn More Here